María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de Semmelweis University](/img/noimage_org.png)
Semmelweis University
Budapest, HungríaPublicacións en colaboración con investigadores/as de Semmelweis University (4)
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
BMC Cancer, Vol. 21, Núm. 1
-
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
British Journal of Haematology, Vol. 193, Núm. 3, pp. 561-569
2018
-
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528